Pralidoxime

Patient with myasthenia gravis. Not indicated for the treatment of poisoning due to carbamate pesticides, phosphorus, inorganic phosphates, or organophosphates without anticholinesterase activity. Renal impairment. Children. Pregnancy and lactation. Monitoring Parameters Monitor blood pressure, heart rate, respiratory rate, muscle fasciculations and strength, pulse oximetry; fluid balance throughout therapy. Perform continuous ECG and haemodynamic monitoring.

Significant: Myasthenic crisis, transient neuromuscular blockade (high doses); worsening of cholinergic effects in rapid IV inj (e.g. tachycardia, laryngospasm, muscle rigidity or paralysis, or cardiac arrest). Eye disorders: Blurred vision, diplopia, impaired accommodation. Gastrointestinal disorders: Nausea, vomiting. Injury, poisoning and procedural complications: Inj site pain (IM). Investigations: Transient increase in AST/ALT, and creatine phosphokinase. Musculoskeletal and connective tissue disorders: Muscle weakness. Nervous system disorders: Headache, dizziness, drowsiness, paralysis, seizures. Renal and urinary disorders: Renal insufficiency. Respiratory, thoracic and mediastinal disorders: Hyperventilation, apnoea. Skin and subcutaneous tissue disorders: Maculopapular rash. Vascular disorders: Hypertension.

Antidotes, Detoxifying Agents & Drugs Used in Substance Dependence

V03AB04 - pralidoxime ; Belongs to the class of antidotes. Used in the management of organo-phosphate poisoning.